The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
The Watchman device is providing protection from blood clots and strokes for those patients at risk because of their AFib.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback